Carl Byrnes
Stock Analyst at Northland Securities
(0.30)
# 4,484
Out of 4,988 analysts
284
Total ratings
36.9%
Success rate
-3.5%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Reiterated: Buy | $7.5 | $1.28 | +485.94% | 3 | Apr 24, 2026 | |
| MDXG MiMedx Group | Reiterated: Buy | $10 → $6 | $4.77 | +25.79% | 27 | Apr 17, 2026 | |
| SPRY ARS Pharmaceuticals | Reiterated: Buy | $25 | $4.11 | +508.27% | 2 | Apr 15, 2026 | |
| RCEL AVITA Medical | Reiterated: Buy | $10 | $11.02 | -9.26% | 2 | Mar 26, 2026 | |
| BLFS BioLife Solutions | Reiterated: Buy | $34 | $36.69 | -7.33% | 37 | Mar 24, 2026 | |
| TLSI TriSalus Life Sciences | Rated: Buy | $13 → $8 | $5.10 | +56.86% | 5 | Mar 23, 2026 | |
| MDAI Spectral AI | Reiterated: Buy | $6 | $1.64 | +265.85% | 12 | Mar 19, 2026 | |
| SNWV SANUWAVE Health | Reiterated: Buy | $55 | $4.55 | +1,108.79% | 4 | Mar 16, 2026 | |
| INDV Indivior Pharmaceuticals | Reiterated: Buy | $50 | $34.88 | +43.35% | 12 | Feb 27, 2026 | |
| BWAY BrainsWay | Reiterated: Buy | $12 → $15 | $13.61 | +10.21% | 14 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.87 | +70.36% | 18 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $4 | $0.3097 | +1,191.57% | 39 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.7139 | n/a | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $1.25 | $13.63 | n/a | 12 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $2.01 | n/a | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $8 → $1 | $0.0001 | n/a | 24 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $2 | $0.0001 | n/a | 24 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $2 | $31.80 | n/a | 30 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.12 | n/a | 12 | May 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $63.06 | n/a | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $17.01 | n/a | 1 | Oct 22, 2018 |
Connect Biopharma Holdings
Apr 24, 2026
Reiterated: Buy
Price Target: $7.5
Current: $1.28
Upside: +485.94%
MiMedx Group
Apr 17, 2026
Reiterated: Buy
Price Target: $10 → $6
Current: $4.77
Upside: +25.79%
ARS Pharmaceuticals
Apr 15, 2026
Reiterated: Buy
Price Target: $25
Current: $4.11
Upside: +508.27%
AVITA Medical
Mar 26, 2026
Reiterated: Buy
Price Target: $10
Current: $11.02
Upside: -9.26%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $36.69
Upside: -7.33%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13 → $8
Current: $5.10
Upside: +56.86%
Spectral AI
Mar 19, 2026
Reiterated: Buy
Price Target: $6
Current: $1.64
Upside: +265.85%
SANUWAVE Health
Mar 16, 2026
Reiterated: Buy
Price Target: $55
Current: $4.55
Upside: +1,108.79%
Indivior Pharmaceuticals
Feb 27, 2026
Reiterated: Buy
Price Target: $50
Current: $34.88
Upside: +43.35%
BrainsWay
Jan 22, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $13.61
Upside: +10.21%
Nov 14, 2025
Reiterated: Buy
Price Target: $10
Current: $5.87
Upside: +70.36%
Nov 5, 2025
Reiterated: Buy
Price Target: $9 → $4
Current: $0.3097
Upside: +1,191.57%
Aug 28, 2025
Reiterated: Buy
Price Target: $5
Current: $0.7139
Upside: n/a
Jul 19, 2023
Rated: Hold
Price Target: $2 → $1.25
Current: $13.63
Upside: n/a
May 22, 2023
Initiated Coverage: Buy
Price Target: $8
Current: $2.01
Upside: n/a
Jan 6, 2023
Downgraded: Sell
Price Target: $8 → $1
Current: $0.0001
Upside: n/a
Nov 23, 2022
Reiterated: Buy
Price Target: $10 → $2
Current: $0.0001
Upside: n/a
Aug 17, 2022
Reiterated: Buy
Price Target: $4 → $2
Current: $31.80
Upside: n/a
May 14, 2020
Rated: Hold
Price Target: n/a
Current: $2.12
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: $45
Current: $63.06
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $17.01
Upside: n/a